Published in Medical Letter on the CDC and FDA, March 10th, 1997
Researchers including John Sbarbaro from the University of Colorado Health Sciences Center and Michael Iseman from Denver's National Jewish Center for Immunology and Respiratory Diseases examined three difference concentrations of ofloxacin in combination with pyrazinamide and determined that all three were active against the multidrug-resistant tuberculous bacilli ("Combined Effect of Pyrazinamide and Ofloxacin Within the Human Macrophage," Tubercle and Lung Disease, December...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.